Haemonetics Director Pedro P. Granadillo Unloads 5,837 Shares (HAE)
Haemonetics (NYSE:HAE) Director Pedro P. Granadillo sold 5,837 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $34.69, for a total transaction of $202,485.53. Following the completion of the transaction, the director now directly owns 14,901 shares in the company, valued at approximately $516,916. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Haemonetics (NYSE:HAE) traded down 1.71% on Tuesday, hitting $34.45. 189,832 shares of the company’s stock traded hands. Haemonetics has a 52-week low of $29.86 and a 52-week high of $45.90. The stock has a 50-day moving average of $33.14 and a 200-day moving average of $37.26. The company has a market cap of $1.793 billion and a price-to-earnings ratio of 52.31.
Haemonetics (NYSE:HAE) last announced its earnings results on Monday, April 28th. The company reported $0.46 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.58 by $0.12. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $244.87 million. During the same quarter last year, the company posted $0.48 earnings per share. Haemonetics’s revenue was down 3.5% compared to the same quarter last year. On average, analysts predict that Haemonetics will post $1.89 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Haemonetics in a research note on Wednesday, May 21st. They now have a $38.00 price target on the stock, up previously from $36.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Haemonetics in a research note on Friday, March 28th. They now have a $34.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $38.00.
Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.